v3.26.3
Schedule of Computation of Basic and Diluted Net Loss Per Share Attributable to Ordinary Shareholders (Details) - Chemomab Therapeutics Ltd [Member] - USD ($)
$ / shares in Units, $ in Thousands
 3 Months Ended 6 Months Ended 12 Months Ended
Jun. 30, 2026
Jun. 30, 2025
Jun. 30, 2026
Jun. 30, 2025
Dec. 31, 2025
Dec. 31, 2024
Dec. 31, 2023
Net loss $ 2,165 $ 2,057 $ 3,938 $ 5,380 $ 8,995 $ 13,945 $ 24,221
Weighted-average number of ordinary shares used in computing net loss per share attributable to ordinary shareholders - basic 640,243,933 [1] 463,508,519 [1] 639,483,242 [1] 459,829,621 [1] 510,227,715 [2] 359,048,638 [2] 234,998,859 [2]
Weighted-average number of ordinary shares used in computing net loss per share attributable to ordinary shareholders - diluted 640,243,933 [1] 463,508,519 [1] 639,483,242 [1] 459,829,621 [1] 510,227,715 [2] 359,048,638 [2] 234,998,859 [2]
Net loss per share attributable to ordinary shareholders, basic $ 0.003 [1] $ 0.004 [1] $ 0.006 [1] $ 0.012 [1] $ 0.018 $ 0.039 $ 0.103
Net loss per share attributable to ordinary shareholders, diluted $ 0.003 [1] $ 0.004 [1] $ 0.006 [1] $ 0.012 [1] $ 0.018 $ 0.039 $ 0.103
[1] 1 American Depositary Share (ADS) represents 80 Ordinary Shares
[2] 1 American Depositary Share (ADS) represents 80 Ordinary Shares.